Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study.

ABSTRACT:

Background

Topoisomerase is an essential enzyme for deoxyribonucleic acid replication, and its inhibitors suppress tumor progression. Amrubicin, a topoisomerase II inhibitor, is mainly used in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). However, the impact of different types of topoisomerase inhibitors for first-line chemotherapy on the efficacy of amrubicin remains unclear. In the present study, we aimed to evaluate the efficacy of second-line amrubicin in patients with relapsed SCLC who were previously treated with platinum-based chemotherapy, including topoisomerase I and II inhibitors.

Methods

This study retrospectively analyzed patients with ES-SCLC who experienced recurrence and were treated with amrubicin at 22 institut

SUBMITTER: Uda S 

PROVIDER: S-EPMC9554692 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature